Comparative effectiveness of herb-partitioned moxibustion plus lifestyle modification treatment for patients with simple obesity: A study protocol for a randomized controlled trial

Li-Hua Wang, Si-Ying Lv, Yi-Ran Liu, Xia Chen, Jia-Jie Wang, Wei Huang, Zhong-Yu Zhou, Li-Hua Wang, Si-Ying Lv, Yi-Ran Liu, Xia Chen, Jia-Jie Wang, Wei Huang, Zhong-Yu Zhou

Abstract

Introduction: Obesity is a global public health issue, which results in many health complications. Moxibustion may serve as an alternative management for simple obesity, where pharmacological therapy is always difficult to be accepted by the majority of obese patients based on its safety. However, the effects of herb-partitioned moxibustion as obesity intervention have not been confirmed. This study is designed as a single-blinded, 3-dummy randomized controlled trial to evaluate the efficacy and safety of herb-partitioned moxibustion plus lifestyle modification treatment in patients with simple obesity.

Methods and analysis: This study will be a randomized, controlled trial conducted from April, 2019 to April, 2021 that includes 108 participants who have simple obesity and meet the eligibility criteria. The participants will be randomly divided into 3 treatment groups: heat application group, medicated plaster group, or herb-partitioned moxibustion group. Each treatment will last 4 weeks. The primary outcomes will be the clinical effectiveness. The secondary outcome measures include participants' obesity-related indicators, the IWQOL-Lite scale, and the syndrome score of Traditional Chinese Medicine. Adverse events will be recorded during the intervention period.

Ethics and dissemination: Ethical approval of this study was granted by the Ethics Committee of Hubei Provincial Hospital of Traditional Chinese Medicine on 15 November 2018 (Ethics Reference No: HBZY2018-C24-01). Written informed consents will be provided by all participants before they were enrolled in this study.

Trial registration number: NCT04606680.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Figures

Figure 1
Figure 1
Flow diagram of the study procedure.

References

    1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. In WHO Technical Report Series 894. Geneva, Switzerland: World Health Organization; 2000.
    1. Ghanemi A, Yoshioka M, St-Amand J. Broken energy homeostasis and obesity pathogenesis: the surrounding concepts. J Clin Med 2018;7:453.
    1. Inoue Y, Qin B, Poti J, et al. Epidemiology of obesity in adults: latest trends. Curr Obes Rep 2018;7:276–88.
    1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease study 2013. Lancet 2014;384:766–81.
    1. Andolfi C, Fisichella PM. Epidemiology of obesity and associated comorbidities. J Laparoendosc Adv Surg Tech A 2018;28:919–24.
    1. Pi-Sunyer X. The medical risks of obesity. Postgrad Med 2009;121:21–33.
    1. Procaccini C, Santopaolo M, Faicchia D, et al. Role of metabolism in neurodegenerative disorders. Metabolism 2016;65:1376–90.
    1. Mazon JN, de Mello AH, Ferreira GK, et al. The impact of obesity on neurodegenerative diseases. Life Sci 2017;182:22–8.
    1. Michopoulos V. Stress-induced alterations in estradiol sensitivity increase risk for obesity in women. Physiol Behav 2016;166:56–64.
    1. Heymsfield SB, Wadden TA, Mechanisms Pathophysiology, and management of obesity. N Engl J Med 2017;376:254–66.
    1. Kang LL, Li YX, Zhou HX. Syndrome differentiation combining moxibustion in the treatment of polycystic ovary syndrome infertility for 43 cases. Chin Med Mod Distance Educ Chin 2015;5:61–2.
    1. Li JY, Tang Y, Yao L. Clinical effect of Chinese medicine, moxibustion and western medicine in treatment of obese patients with infertility caused by polycystic ovary syndrome. World Chin Med 2017;2:331–3.
    1. Wen JY. Effects of moxibustion on intestinal flora in obese rats. Guangxi University of traditional Chinese Medicine 2019.
    1. Chang SN. Chinese Acupuncture. 3rd ed.Beijing: People Sanitation; 1995.
    1. Pacific OROF, WRPO W. The Asia-Pacific Perspective: Redefining Obesity and its Treatment. Geneva, Switzerland: World Health Organization; 2000.
    1. Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906–13.
    1. Kate Hunt, Sally Wyke, Gray Cindy M, et al. A gender-sensitised weight loss and healthy living programme for overweight and obese men delivered by Scottish Premier League football clubs(FFIT): a pragmatic randomised controlled trial. Lancet 2014;383:1–20.
    1. Seki Y, Kasama K, Yasuda K, et al. Metabolic surgery for inadequately controlled type 2 diabetes in non-severely obese Japanese: a prospective, single center study. Beijing, China: China Standard Press; 2006.
    1. Pournaras Dimitri J, Hardwick RH, le Roux Carel W. Gastrointestinal surgery for obesity and cancer: 2 sides of the same coin. Surg Obes Relat Dis 2017;14:978–85.
    1. Nam HK, Lee KH. Small for gestational age and obesity: epidemiology and general risks 2018;23:9–13.
    1. Zhang B, Dong J, Zhou Z. Traditional Chinese Internal Medicine. Shanghai: Shang Hai Science and Technology Press; 1985.
    1. Xie J, Li M, Han C. Chinese Internal Medicine. Beijing: People's Medical Publishing House; 2013.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir